Nektar Therapeutics (NKTR)
- Previous Close
0.6872 - Open
0.6673 - Bid 0.5580 x 100
- Ask 0.7445 x 100
- Day's Range
0.6340 - 0.6871 - 52 Week Range
0.4300 - 1.9300 - Volume
1,460,691 - Avg. Volume
2,469,713 - Market Cap (intraday)
127.89M - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5800 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.92
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
www.nektar.comRecent News: NKTR
View More
Performance Overview: NKTR
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKTR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKTR
View MoreValuation Measures
Market Cap
119.48M
Enterprise Value
-33.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.34
Price/Book (mrq)
1.97
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-120.86%
Return on Assets (ttm)
-23.14%
Return on Equity (ttm)
-124.10%
Revenue (ttm)
98.43M
Net Income Avi to Common (ttm)
-118.96M
Diluted EPS (ttm)
-0.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
255.23M
Total Debt/Equity (mrq)
319.97%
Levered Free Cash Flow (ttm)
-43.69M
Research Analysis: NKTR
View MoreResearch Reports: NKTR
View MoreLowering target price to $0.58
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.584000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $0.63
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.632000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $0.93
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.928000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about NKTR?
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $1.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target